Eli Lilly ·
Eli Lilly filed a series of lawsuits from mid-2024 through 2026 against compounding pharmacies, telehealth platforms, and related entities producing or selling compounded tirzepatide. The cases assert a combination of claims including trademark infringement, unfair competition, false advertising, and state consumer protection violations. Lilly has explicitly declined to rely on FDCA claims — which are generally not available to private parties — and instead built its cases on the Lanham Act, state little-FTC statutes, and common-law unfair competition. The litigation strategy has evolved from targeted actions against specific bad actors to broader sweeps of telehealth operators, and has generated substantial case law through 2025 and into 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.